comparemela.com

Page 8 - Blueprint Medicine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines AYVAKIT® (avapritinib) in gastrointestinal stromal tumors

QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines AYVAKIT® (avapritinib) in gastrointestinal stromal tumors
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Blueprint Medicines Co Expected to Post Q1 2024 Earnings of ($2 24) Per Share (NASDAQ:BPMC)

Blueprint Medicines Co Expected to Post Q1 2024 Earnings of ($2 24) Per Share (NASDAQ:BPMC)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective August 1, 2023, the Compensation Committee of Blueprint.

Blueprint Medicines Reports Second Quarter 2023 Results

Analyzing Zai Lab (NASDAQ:ZLAB) & Blueprint Medicines (NASDAQ:BPMC)

Zai Lab (NASDAQ:ZLAB – Get Free Report) and Blueprint Medicines (NASDAQ:BPMC – Get Free Report) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability. Institutional and Insider Ownership 54.0% of Zai […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.